Hong Mou

Hong Mou

Auto-generated profile, based on publicly available information

Hong Mou

School of Psychology, Shanghai University of Sport, Shanghai, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2022 in Physiology & Behavior
Verified
Journal Article
Closed access
HMHong Mou
Hong Mou
QFQun Fang
Qun Fang
Tian ShudongTian Shudong
Tian Shudong
Fanghui QiuFanghui Qiu
Fanghui Qiu

1 October 2025 in Behavioral and Brain Functions
Verified
Journal Article
Open access
PDF file
HMHong Mou
Hong Mou
LLLikai Liu
Likai Liu
YWYingying Wang
Yingying Wang
Multivariate neuroimaging studies have shown a functional dissociation between the temporal and frontoparietal cortices in action representation. However, it remains unclear to what extent this specificity is modulated by motor experience. To address this question, we employed functional magnetic resonance imaging-based multivoxel pattern analysis (MVPA). Neural activation patterns were compared between professional table tennis players (experts) and novices during the passive observation of action videos and the reading of corresponding action-related sentences. Specifically, to identify brain regions that decode perceptual–motor information, classifiers were trained and tested within the same stimulus modality (video or sentence). To identify brain regions supporting conceptual-level action decoding, classifiers trained on video stimuli were tested on sentence stimuli, and vice versa. The results revealed that, in experts, the left lateral posterior temporal cortex (LPTC) and anterior temporal lobe (ATL) supported crossmodal action representations, whereas the left superior parietal lobule (SPL) and precentral gyrus (PreCG) exhibited modality-specific representations, particularly in response to video-based stimuli. In novices, only the PreCG showed modality-specific representations for video stimuli. These findings suggest a functional dissociation across brain regions, with the temporal cortex involved in conceptual-level representations of actions andthe SPL associated with processing perceptual–motor features. While such representations were more prominent in experts for familiar actions, the PreCG showed modality-specific representations regardless of group. These results highlight potential group-level differences in the neural encoding of action-related information, which may reflect the influence of task familiarity or prior sensorimotor experience.

3 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JDJiaqi Duan
Jiaqi Duan
ZLZhi-De Liang
Zhi-De Liang
HMHong Mou
Hong Mou
YYYingdanni Yu
Yingdanni Yu
HWHongyu Wu
Hongyu Wu
STShudong Tian
Shudong Tian
Purpose: To compare the efficacy and safety of five single-target glucagon-like peptide-1 receptor agonists (GLP-1RAs) in adults with overweight or obesity and explore whether trial-level physical activity (PA)/lifestyle support modified treatment effects.Methods: We searched PubMed, Embase, Web of Science, Cochrane Library, and Scopus from inception to April 2026 for randomized controlled trials evaluating liraglutide, semaglutide, exenatide, dulaglutide, or lixisenatide (≥4 weeks). Bayesian random-effects network meta-analyses assessed weight-related outcomes, HbA1c, and safety outcomes. Exploratory analyses examined the effects of PA/lifestyle support and dose. This review was registered in PROSPERO (CRD420261389913).Results: Ninety-six trials involving 220 treatment arms were included. Semaglutide showed the greatest estimated reductions in body weight (MD −12.71 kg, 95% CrI −16.43 to −9.05), HbA1c (MD −1.33%, 95% CrI −2.42 to −0.29), percentage weight change (MD −14.79%, 95% CrI −19.31 to −10.18), and waist circumference (MD −11.99 cm, 95% CrI −15.77 to −8.19), although certainty of evidence for efficacy outcomes was very low. PA/lifestyle support was associated with additional weight reduction (MD −2.08 kg, 95% CrI −3.63 to −0.54) in one comparison, while other effects were uncertain. Semaglutide increased risks of treatment discontinuation due to adverse events, nausea, and vomiting, but not serious adverse events.Conclusion: Among five single-target GLP-1RAs, semaglutide demonstrated the greatest estimated efficacy but higher gastrointestinal intolerance. Trial-level PA/lifestyle support may contribute to heterogeneity in weight outcomes, whereas no consistent dose-related pattern was observed. Treatment selection should consider efficacy, tolerability, patient characteristics, and evidence certainty.